Company / Current Assets
Apellis Pharmaceuticals, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$1.0B
FY2025
5-year range
$719.5M / $1.0B
FY2021-FY2025
Trend
+28.6%
vs FY2024
Sector context
#48 of 213
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s current assets of $1.0B is higher than 77% of companies in the Health Care sector (FY2025). Current Assets has increased for 3 consecutive years, from $720M in FY2022 to $1.0B in FY2025.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of +2.0%. Top quartile in the Health Care sector.
Improved from $766M to $1.0B over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +12.1%
- 5-Year CAGR
- +2.0%
- 10-Year CAGR
- -
Sector benchmark
-59.8% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s current assets has grown for 3 consecutive years.
- 5-year CAGR of +2.0%, indicating consistent growth.
- In FY2025, current assets increased 28.6% year-over-year.
- Ranks #48 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | +28.6% |
| FY2024 | $789.0M | +3.0% |
| FY2023 | $766.3M | +6.5% |
| FY2022 | $719.5M | -12.7% |
| FY2021 | $824.0M | -10.2% |
| FY2020 | $917.2M | +145.8% |
| FY2019 | $373.1M | +84.3% |
| FY2018 | $202.4M | +11.2% |
| FY2017 | $182.0M | +565.0% |
| FY2016 | $27.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026